Waldencast plc (WALD) AI Stock Analysis

Waldencast plc develops, markets, and distributes skin health products across the skincare sector. The company's portfolio features approximately 200 cosmetic, over-the-counter, and prescription products under brands including Obagi Medical, Obagi Clinical, and Obagi Professional. Its offerings address both aesthetic enhancement and therapeutic skincare needs. A key offering is the Skintrinsiq device, which delivers facial treatments and is used by dermatologists, plastic surgeons, and aestheticians in clinical settings, spas, and medical centers. Founded in 1988 and based in White Plains, New York, Waldencast distributes its products through a direct sales force and strategic distribution partnerships.

Waldencast grew revenue from $94.4M in FY2020 to $272.1M in FY2025, reflecting a 4-year revenue CAGR of 30.3%. However, annual revenue fell 0.7% in FY2025 following growth of 25.5% in FY2024 and 53.1% in FY2023. Profitability has faced challenges, with gross margin narrowing from 69.2% in FY2020 to 45.5% in FY2025. Operating margin was -22.7% in FY2025, and net loss expanded to -$229.7M, resulting in a net margin of -84.4% and an EPS of -$0.37. Over the trailing twelve months, revenue was $237.3M with an operating margin of -156.9%. In the latest quarter ended June 30, 2026, revenue dropped 80.3% year-over-year.

As of June 30, 2026, Waldencast held $7.8M in cash and short-term investments compared to total debt of $149.3M, leaving net debt at $141.5M. Total assets stood at $646.7M alongside shareholders' equity of $391.2M, yielding a debt-to-equity ratio of 0.38 and a current ratio of 4.80. In FY2025, the company used -$12.8M in operating cash flow and incurred capital expenditures of $3.4M, resulting in free cash flow of -$16.2M. Over the past five years, the company's share count increased 171.6%.

Waldencast carries a market capitalization of $111.9M and an enterprise value of $251.4M. Its forward P/E multiple is 45.0x, above the median of 14.3x for its US-listed Consumer Defensive peers. Its enterprise value-to-EBITDA ratio of 13.9x is higher than the peer median of 11.7x, while its price-to-sales ratio of 0.5x trades below the peer median of 0.7x. The stock has dropped 58.3% over the past year and 91.3% over five years, lagging the S&P 500 (SPY), which gained 17.3% and 85.1% over those respective periods.

Waldencast has a mean analyst price target of $2.05, representing 141.2% upside compared to its last close of $0.85 on October 15, 2026. For the fiscal year ending December 31, 2026, consensus estimates project an EPS of -$0.50 and revenue of $286.6M. For the following fiscal year, 1 analyst projects revenue of $317.6M, representing 10.8% growth, and an EPS of -$0.44. The company has beaten EPS expectations in 2 of the past 4 quarters.

This page is an AI-written research summary of Waldencast plc (WALD). The text was generated on October 30, 2026 from Quotelinks data as of October 15, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: WALD income statement, WALD balance sheet, WALD key metrics, WALD analyst forecast, WALD chart. See the WALD stock overview for the latest quote and news.